Stay updated on Pembrolizumab for Refractory Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page.

Latest updates to the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page
- Check4 days agoChange DetectedRevision: v3.3.2 is now shown replacing v3.2.0; this is a minor admin update with no changes to study content, eligibility criteria, outcomes, or contacts; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check12 days agoChange DetectedRemoved the government funding/operating status notice from the page; the banner previously informing visitors about potential delays and NIH operating status is no longer displayed. Core study details, eligibility criteria, and contact information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe two screenshots show no substantive changes to the study data (title, conditions, eligibility, locations, enrollment, or outcomes), only minor UI/layout differences. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check55 days agoChange DetectedUpdated page to v3.2.0 with a broad government-operating-status notice; removed a specific resource entry (Carcinoma of esophagus) from the Genetic and Rare Diseases Information Center, and retained general references to NIH/C cc and related sites.SummaryDifference3%

- Check62 days agoChange DetectedUpdate the page version from v3.0.2 to v3.1.0, reflecting a newer release metadata.SummaryDifference0.1%

- Check76 days agoChange DetectedUpdated core content: Revision updated from v3.0.1 to v3.0.2. Removed 'Back to Top' as a minor UI change.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab for Refractory Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page.